Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)

NCT03434158 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

DRUG: Olaparib

Sponsor

Spanish Oncology Genito-Urinary Group

Collaborators

[object Object]
[object Object]